Filing Details

 

CUSIP No. 63010B200

13D

 

 

1.		NAMES OF REPORTING PERSONS Cara M. Finnegan
2.		CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions) (a)    ☐ (b)    ☐ (joint filers)
3.		SEC USE ONLY
4.		SOURCE OF FUNDS (see instructions)  PF
5.		CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     ☐
6.		CITIZENSHIP OR PLACE OF ORGANIZATION   United States

 

Item 1.  Security and Issuer.

 

 The securities to which this statement on Schedule 13D (this “Statement”) relates to the Common Stock, par value $0.00001 and Series C Preferred Stock, par value $.00001 of Nano Mobile Healthcare, Inc. (the “Issuer”).  The principal executive offices of the Issuer are located at One Boston Place Suite 2600, Boston, MA 02108.

 

Item 2.  Identity and Background.

 

 (a)  This Statement is filed by Cara M. Finnegan (the “Reporting Person”).

 

(b)   The address of the principal business and principal office of the Reporting Person is 514 Americas Way #7697 Box Elder, SD 57719-7600.

 

(c)   The Reporting Person is the Trustee and 50% beneficiary of the John E. Groman Irrevocable Trust, under declaration of trust dated 5/20/2014 and of the 50% beneficiary of the Groman Finnegan Investment Trust, under declaration of trust dated 1/18/2002.

 

(d)   During the past five years, the Reporting Person has not been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

 

(e)   During the past five years, the Reporting Persons has not been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding such person was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

 

Item 3.  Source or Amount of Funds or Other Consideration.

 

The shares of common stock and Series C Preferred Stock represent an investment in the Issuer made from the personal funds of the Reporting Person.  The total amount paid by the Reporting Person for the common stock and the Series C Preferred Stock is $154,642.99

 

Item 4.  Purpose of Transaction.

 

The Reporting Person, as the beneficial owner of the securities of the Issuer, holds such securities for investment purposes. Depending on the factors discussed herein, the Reporting Person may, from time to time, acquire, directly or indirectly, additional shares of common stock and other securities and/or retain and/or sell all or a portion of the shares of common stock and/or the Series C Preferred Stock after converting to common stock, held by the Reporting Person in the open market or in privately negotiated transactions. Any actions the Reporting Person might undertake will be dependent upon the Reporting Person’s review of numerous factors, including, among other things, the price levels of the common stock and, general market and economic conditions, ongoing evaluation of the Issuer's business, financial condition, operations and prospects; the relative attractiveness of alternative business and investment opportunities, and other future developments. Except as set forth above, the Reporting Person has no present plans or intentions which would result in or relate to any of the transactions described in subparagraphs (a) through (j) of Item 4 of Schedule 13D.

 

Item 5.  Interest in Securities of the Issuer.

 

(a) The Reporting Person has sole voting power over 300,000 shares of Common Stock and 24,175 shares of Series C Preferred Stock, convertible into 483,504,170 shares of Common Stock.   These combined shares represent 18.5% of the total outstanding shares of Common Stock of the Company if all preferred shares were converted to common and all common due shareholders are issued.

 

(b) The Reporting Person is the beneficial owner of 457,500 shares of Common Stock and 34,248 shares of Series C Preferred Stock, convertible into 684,964,240 shares of Common Stock.  These combined shares represent 26.2% of the total outstanding shares of Common Stock of the Company if all preferred shares were converted to common and all common due shareholders are issued.

 

(c)  Except as set forth in this Schedule 13D, the Reporting Person has not effected any transactions with respect to the shares of the Common Stock or Series B Preferred Stock or Series C Preferred Stock or Series D Preferred Stock during the past 60 days.

 

 

(d) No other person is known to the Reporting Person to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares of common stock or Series B Preferred Stock or Series C Preferred Stock or Series D Preferred Stock during covered by this Statement.

 

(e) Not applicable.

 

Item 6.  Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.

 

None.

 

Item 7.  Material to Be Filed as Exhibits.

 

None.

 

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

---